Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices

Hidefumi Higashi, Takashi Matsumata, Tohru Utsunomiya, Nobuhiro Koyanagi, Makoto Hashizume, Keizo Sugimachi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Twenty-two cirrhotic patients with hepatocellular carcinoma (HCC) and concomitant esophageal varices underwent aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both (group A). To evaluate this treatment, 37 cirrhotic patients without esophageal varices who underwent hepatic resection for small HCC (2 cm or less) during the same period (group B) were studied to compare clinical data, preoperative laboratory data, pathologic findings, disease-free rates, and survival rates. The operative time, blood loss, and resected liver weight did not differ between the two groups; however, the tumor size of group A (2.7±1.6 cm, mean±SD) was significantly larger than that of group B (1.5±0.3 cm). The preoperative liver function of group A was also more severe than that of group B except for prothrombin time. Despite these disadvantages, the 1-, 3-, and 5-year disease-free rates of the two groups were 72% versus 94%, 48% versus 54%, and 38% versus 45%, respectively, and the 1-, 3-, and 5-year survival rates were 91% versus 97%, 79% versus 79%, and 54% versus 67% (group A versus group B), respectively, which showed no significant differences. Furthermore, there was no variceal bleeding in group A after treatment. Based on the above findings, for treatment of HCC and concomitant esophageal varices, aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both is the preferred form of treatment.

Original languageEnglish
Pages (from-to)398-402
Number of pages5
JournalWorld journal of surgery
Volume17
Issue number3
DOIs
Publication statusPublished - May 1 1993

Fingerprint

Esophageal and Gastric Varices
Hepatocellular Carcinoma
Liver
Sclerotherapy
Survival Rate
Therapeutics
Injections
Prothrombin Time
Operative Time
Disease-Free Survival
Hemorrhage
Weights and Measures
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Higashi, H., Matsumata, T., Utsunomiya, T., Koyanagi, N., Hashizume, M., & Sugimachi, K. (1993). Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices. World journal of surgery, 17(3), 398-402. https://doi.org/10.1007/BF01658710

Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices. / Higashi, Hidefumi; Matsumata, Takashi; Utsunomiya, Tohru; Koyanagi, Nobuhiro; Hashizume, Makoto; Sugimachi, Keizo.

In: World journal of surgery, Vol. 17, No. 3, 01.05.1993, p. 398-402.

Research output: Contribution to journalArticle

Higashi, H, Matsumata, T, Utsunomiya, T, Koyanagi, N, Hashizume, M & Sugimachi, K 1993, 'Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices', World journal of surgery, vol. 17, no. 3, pp. 398-402. https://doi.org/10.1007/BF01658710
Higashi H, Matsumata T, Utsunomiya T, Koyanagi N, Hashizume M, Sugimachi K. Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices. World journal of surgery. 1993 May 1;17(3):398-402. https://doi.org/10.1007/BF01658710
Higashi, Hidefumi ; Matsumata, Takashi ; Utsunomiya, Tohru ; Koyanagi, Nobuhiro ; Hashizume, Makoto ; Sugimachi, Keizo. / Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices. In: World journal of surgery. 1993 ; Vol. 17, No. 3. pp. 398-402.
@article{ef71fe65f08a4b5ca50488a3060743c9,
title = "Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices",
abstract = "Twenty-two cirrhotic patients with hepatocellular carcinoma (HCC) and concomitant esophageal varices underwent aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both (group A). To evaluate this treatment, 37 cirrhotic patients without esophageal varices who underwent hepatic resection for small HCC (2 cm or less) during the same period (group B) were studied to compare clinical data, preoperative laboratory data, pathologic findings, disease-free rates, and survival rates. The operative time, blood loss, and resected liver weight did not differ between the two groups; however, the tumor size of group A (2.7±1.6 cm, mean±SD) was significantly larger than that of group B (1.5±0.3 cm). The preoperative liver function of group A was also more severe than that of group B except for prothrombin time. Despite these disadvantages, the 1-, 3-, and 5-year disease-free rates of the two groups were 72{\%} versus 94{\%}, 48{\%} versus 54{\%}, and 38{\%} versus 45{\%}, respectively, and the 1-, 3-, and 5-year survival rates were 91{\%} versus 97{\%}, 79{\%} versus 79{\%}, and 54{\%} versus 67{\%} (group A versus group B), respectively, which showed no significant differences. Furthermore, there was no variceal bleeding in group A after treatment. Based on the above findings, for treatment of HCC and concomitant esophageal varices, aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both is the preferred form of treatment.",
author = "Hidefumi Higashi and Takashi Matsumata and Tohru Utsunomiya and Nobuhiro Koyanagi and Makoto Hashizume and Keizo Sugimachi",
year = "1993",
month = "5",
day = "1",
doi = "10.1007/BF01658710",
language = "English",
volume = "17",
pages = "398--402",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Successful treatment of early hepatocellular carcinoma and concomitant esophageal varices

AU - Higashi, Hidefumi

AU - Matsumata, Takashi

AU - Utsunomiya, Tohru

AU - Koyanagi, Nobuhiro

AU - Hashizume, Makoto

AU - Sugimachi, Keizo

PY - 1993/5/1

Y1 - 1993/5/1

N2 - Twenty-two cirrhotic patients with hepatocellular carcinoma (HCC) and concomitant esophageal varices underwent aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both (group A). To evaluate this treatment, 37 cirrhotic patients without esophageal varices who underwent hepatic resection for small HCC (2 cm or less) during the same period (group B) were studied to compare clinical data, preoperative laboratory data, pathologic findings, disease-free rates, and survival rates. The operative time, blood loss, and resected liver weight did not differ between the two groups; however, the tumor size of group A (2.7±1.6 cm, mean±SD) was significantly larger than that of group B (1.5±0.3 cm). The preoperative liver function of group A was also more severe than that of group B except for prothrombin time. Despite these disadvantages, the 1-, 3-, and 5-year disease-free rates of the two groups were 72% versus 94%, 48% versus 54%, and 38% versus 45%, respectively, and the 1-, 3-, and 5-year survival rates were 91% versus 97%, 79% versus 79%, and 54% versus 67% (group A versus group B), respectively, which showed no significant differences. Furthermore, there was no variceal bleeding in group A after treatment. Based on the above findings, for treatment of HCC and concomitant esophageal varices, aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both is the preferred form of treatment.

AB - Twenty-two cirrhotic patients with hepatocellular carcinoma (HCC) and concomitant esophageal varices underwent aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both (group A). To evaluate this treatment, 37 cirrhotic patients without esophageal varices who underwent hepatic resection for small HCC (2 cm or less) during the same period (group B) were studied to compare clinical data, preoperative laboratory data, pathologic findings, disease-free rates, and survival rates. The operative time, blood loss, and resected liver weight did not differ between the two groups; however, the tumor size of group A (2.7±1.6 cm, mean±SD) was significantly larger than that of group B (1.5±0.3 cm). The preoperative liver function of group A was also more severe than that of group B except for prothrombin time. Despite these disadvantages, the 1-, 3-, and 5-year disease-free rates of the two groups were 72% versus 94%, 48% versus 54%, and 38% versus 45%, respectively, and the 1-, 3-, and 5-year survival rates were 91% versus 97%, 79% versus 79%, and 54% versus 67% (group A versus group B), respectively, which showed no significant differences. Furthermore, there was no variceal bleeding in group A after treatment. Based on the above findings, for treatment of HCC and concomitant esophageal varices, aggressive hepatic resection accompanied by simultaneous devascularization, perioperative endoscopic injection sclerotherapy, or both is the preferred form of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0027215249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027215249&partnerID=8YFLogxK

U2 - 10.1007/BF01658710

DO - 10.1007/BF01658710

M3 - Article

C2 - 8393254

AN - SCOPUS:0027215249

VL - 17

SP - 398

EP - 402

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 3

ER -